BOSTON – RA Capital Healthcare Fund, L.P. has executed a series of purchases involving Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) common stock, acquiring 531,326 shares with a total valuation of $4,599,903. The acquisition activity was distributed across three distinct transaction windows between June 12 and June 16, 2026. The per-share acquisition costs varied between $8.31 and $9.00, indicating a strategic accumulation phase within a specific price corridor.
The timing of this capital deployment warrants scrutiny given the stock's recent performance trajectory. ARTV shares have appreciated by 341% over the trailing twelve-month period. Despite this momentum, valuation metrics suggest the stock currently trades above the fair value estimates provided by InvestingPro, a classification that places it on the platform's list of most overvalued equities. The company's aggregate market capitalization stands at $446 million.
Detailing the execution of the purchases, the fund initiated its position on June 12 by acquiring 391,019 shares. These initial shares were obtained through multiple transactions at a weighted average price of $8.57 per share, with individual fill prices ranging from $8.31 to $8.64. The accumulation continued on June 15, when the fund purchased an additional 15,414 shares at a weighted average price of $8.99, with transaction prices clustering between $8.96 and $9.00. The final reported transaction occurred on June 16, involving the purchase of 124,893 shares at a weighted average price of $8.89, with prices ranging from $8.63 to $9.00.
Market data indicates heightened short-term volatility and investor interest. According to InvestingPro data, the stock posted a significant 22.6% return over the last week alone. This performance is highlighted as one of 12 exclusive ProTips available to subscribers analyzing ARTV’s investment potential, suggesting active monitoring of the asset by institutional analysts.
The shares are held indirectly by RA Capital Healthcare Fund, L.P. RA Capital Management, L.P. serves as the investment manager for RA Capital Healthcare Fund, L.P., as well as for RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., and a separately managed account. Peter Kolchinsky and Rajeev Shah are managing members of RA Capital Management GP, LLC, the general partner of RA Capital Management, L.P. Laura Stoppel, a Principal of RA Capital Management, L.P., serves as a director on Artiva Biotherapeutics’ board, providing a direct link between the investment manager and the issuer's governance structure.
Following these recent transactions, the total indirect holdings attributable to the RA Capital group have expanded significantly. RA Capital Healthcare Fund, L.P. now holds 16,763,043 shares of Artiva Biotherapeutics common stock. Additionally, RA Capital Nexus Fund, L.P. holds 264,571 shares, RA Capital Nexus Fund III, L.P. holds 826,832 shares, and a separately managed account holds 68,320 shares. These figures bring the total indirect holdings attributable to the RA Capital group to 17,922,766 shares.
Artiva Biotherapeutics continues to advance its clinical pipeline, notably receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its rheumatoid arthritis treatment, AlloNK in combination with rituximab. This designation facilitates expedited development and review processes, enabling early and frequent interactions with the FDA. Furthermore, Artiva presented clinical data at the European Alliance of Associations for Rheumatology Congress, demonstrating that 71% of patients with refractory rheumatoid arthritis achieved an ACR50 response after six months of follow-up in a Phase 2a trial.
Analyst sentiment remains constructive. Cantor Fitzgerald reiterated its Overweight rating and set a $40.00 price target for Artiva Biotherapeutics, following a webinar with the company’s CEO, Fred Aslan. The discussion focused on the AlloNK therapy’s safety profile and strategic direction. Concurrently, Artiva announced executive changes, including the resignation of Diego Miralles, M.D. from the board of directors as he assumes the role of President and Head of Research and Development. His resignation reduced the board from eight to seven members.
The confluence of institutional buying, regulatory milestones, and clinical data presentation underscores the dynamic nature of Artiva Biotherapeutics' current valuation and strategic position within the biotechnology sector.